Supported by National Institutes of Health (NIH; Bethesda, MD, USA) Grant T32-EY007043 (EB), NIH Grants R01-EY023591, P30-EY003176, Foundation Fighting Blindness (AR, JD; Columbia, MD, USA), NIH Grant EY002162, FDA-OOPD grant R01-41001 (JD; Silver Spring, MD, USA), Research to Prevent Blindness (New York, NY, USA), The Claire Giannini Fund (JD; San Carlos, CA, USA), Hope for Vision (JD; Hollywood, FL, USA), The Bright Focus Foundation (JD; Clarksburg, MD, USA), The Bernard A. Newcomb Macular Degeneration Fund (JD; Mountain View, CA, USA), and That Man May See, Inc. (JD; San Francisco, CA, USA).
Disclosure: E. Bensinger, C. Light Technologies (C); N. Rinella, None; A. Saud, None; P. Loumou, None; K. Ratnam, None; S. Griffin, None; J. Qin, None; T.C. Porco, None; A. Roorda, P; J.L. Duncan, Neurotech USA Inc. (F), Allergan (F), Acucela (F), NightstaRx (F), Second Sight Medical Products (F), AGTC (S), ProQR Therapeutics (C, R, S), Spark Therapeutics (S), SparingVision (S), Editas Medicine Inc. (C), Ophthotech (C), Wave Life Sciences (C)